Our Blog

We would like to introduce you the AbilityPharma’s team

September 25, 2018

If there is something that distinguishes our company, it is the team of professionals that works in it and that is making our project possible, achieving the development of ABTL0812.
 
In Ability Pharma we have an experienced management team with great success in the management of Biotech companies, research and development of drugs, establishment of licensing agreements with multinational companies, specifically in China and Japan, and in obtaining approval of medicines by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
 
Our company is also backed by a highly qualified team of advisors, not only in the medical or scientific field, but also in intellectual property, legal or strategic matters.
 
We cannot forget, the soul of this company, our researchers. We have created an excellent research group consisting of a postdoctoral researcher, a doctoral student and a research technician, who perform all experimental procedures in cell biology, molecular biology, proteomics and animal models for human cancers.
 
Ability Pharma collaborates actively with other public institutions and research groups from different universities, research centers and hospitals (Vall d'Hebron-VHIO, Hospital Clínico-IDIBAPS, IRBLleida, UdG, Bellvitge University Hospital), creating a network of expert scientists who share their knowledge, experience and results. Together, we build an excellent team to succeed in our project and achieve our main objective; to get cancer to stop being a deadly disease.
 
Why investing in Ability Pharma?
 
The investment round opened on September 12 through the crowdfunding campaign #notwithoutyou, presents an excellent investment opportunity since, if the project succeeds, we calculate that a global license of the drug ABTL0812 can reach more than $ 350 million, giving an investment return of x7 to current partners.
 
It is important to highlight that there is a high risk when investing in biotechnology companies, since the possibility that a drug that is currently in phase 2 reaches the market is around 20%. Even so, in case of success, the returns are very high, with a very positive social impact.
 
Would you like to know more about our project? Do not hesitate to send us an email to the following address: contact@abilitypharma.com

LATEST NEWS

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG